BACKGROUND
Despite improved outcomes with immune checkpoint inhibitor (ICI) combinations in metastatic renal cell carcinoma (mRCC), reliable biologically-driven prognostic markers remain needed. The CHOMET study evaluated tumor ABCA1/ABCG1 expression and their association with systemic lipid parameters, nutritional sta...
G. C. Giudice, Hassan M. Abushukair, G. Mazzaschi et al.· The Oncologist· 0 citations
524
Background:
Antibody-drug conjugates (ADCs) are increasingly used in cancer care; toxicities like Antibody-Drug Conjugate Associated Pneumonitis (AAP) have emerged as clinically significant & fatal adverse events. Data characterizing AAP across phase 1 trials is limited.
Methods:
We retrospectively collec...
Falah Fayaz, A. Aijaz, Hassan M. Abushukair et al.· JCO Oncology Practice· 0 citations
KRAS G13X mutations represent a small but clinically meaningful subset of NSCLC defined by a distinctive co-mutation pattern and Combinational therapeutic strategies addressing these vulnerabilities can help improve outcomes.
Benjamin J. Staum, Rachaita Lakra, A. Ravindra et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.